FDA Panel Endorses Unproven Peptides
An advisory panel to the U.S. Food and Drug Administration has endorsed a class of peptides that lack established proof of safety or efficacy. The decision could pave the way for broader use of these unregulated compounds, raising concerns among experts about potential health risks and premature access to unvetted treatments.